Stemline Therape buy melinda
Start price
10.08.18
/
50%
€13.53
Target price
29.08.18
€15.06
Performance (%)
11.33%
End price
29.08.18
€15.06
Summary
This prediction ended on 29.08.18 with a price of €15.06. The BUY prediction by melinda finished with a performance of 11.33%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Stemline Therape | - | - | - | - |
iShares Core DAX® | 1.560% | 4.721% | 18.671% | 17.397% |
iShares Nasdaq 100 | 0.517% | 1.171% | 23.619% | 35.896% |
iShares Nikkei 225® | 1.730% | 6.073% | 16.253% | 10.295% |
iShares S&P 500 | 1.482% | 1.218% | 23.290% | 38.843% |
Comments by melinda for this prediction
In the thread Stemline Therape diskutieren
SecteurRecherche biotechnologique et médicale Agenda 14/11 Publication de résultats
Engages in the discovering, acquiring, developing and commercializing proprietary therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need.
Its clinical stage product candidates include SL-401, SL-801, and SL-701.
The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies.
The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies.
The SL-701, is an immunotherapy designed to activate the immune system to attack tumors.
The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need.
Its clinical stage product candidates include SL-401, SL-801, and SL-701.
The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies.
The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies.
The SL-701, is an immunotherapy designed to activate the immune system to attack tumors.
The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Nombre d'employés : 37 personnes.
(Zielkurs erreicht)
Stopped prediction by melinda for Stemline Therape
Stemline Therape
Start price
Target price
Perf. (%)
€18.55
19.06.13
19.06.13
€20.00
19.12.13
19.12.13
-26.17%
19.12.13
19.12.13